Literature DB >> 1825058

Soluble Fc gamma receptors II (Fc gamma RII) are generated by cleavage of membrane Fc gamma RII.

C Sautès1, N Varin, C Teillaud, M Daëron, J Even, P M Hogarth, W H Fridman.   

Abstract

This study describes the production of soluble Fc gamma RII by a cell line, D1B1, obtained by transfection of mouse L cells with a murine beta 1 Fc gamma RII cDNA. Upon incubation at 37 degrees C, radioiodinated D1B1 cells release a 39-kDa soluble Fc gamma RII, reacting with the rat anti-mouse Fc gamma RII monoclonal antibody 2.4G2, and binding to mouse IgG2a, IgG2b and IgG1 but not IgG3. In contrast to the transmembrane 50- to 70-kDa receptor, this soluble Fc gamma RII does not react with antibodies directed against a peptide corresponding to the 15 carboxy-terminal intracytoplasmic amino acids of beta Fc gamma RIII. N-Glycosidase F treatment generates a 18-kDa polypeptide. A 32- to 40-kDa soluble Fc gamma RII, which resolves into 18.5- and 20-kDa polypeptides after deglycosylation, was also isolated from the culture medium of unlabeled D1B1 cells. Therefore, this study indicates that soluble Fc gamma RII corresponding to the two extracellular domains of Fc gamma RII are generated by cleavage of membrane Fc gamma RII. Proteolysis occurs most probably at the vicinity of the transmembrane region of the receptor, around amino acids 165 to 180.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825058     DOI: 10.1002/eji.1830210135

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Murine soluble Fc gamma receptors/IgG-binding factors (IgG-BF): analysis of the relation to Fc gamma RII and production of milligram quantities of biologically active recombinant IgG-BF.

Authors:  C Sautès; N Mazières; A Galinha; E Tartour; C Bonnerot; S Amigorena; C Teillaud; R Spagnoli; W H Fridman
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship.

Authors:  E Fiebiger; F Hammerschmid; G Stingl; D Maurer
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

Review 3.  FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

Authors:  Kenneth G C Smith; Menna R Clatworthy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

4.  Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.

Authors:  E Rajnavölgyi; G Fazekas; J Lund; M Daeron; J L Teillaud; R Jefferis; W H Fridman; J Gergely
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

5.  Increased levels of soluble low-affinity Fc gamma receptors (IgG-binding factors) in the sera of tumour-bearing mice.

Authors:  A Lynch; E Tartour; J L Teillaud; B Asselain; W H Fridman; C Sautès
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

6.  Peripheral membrane molecules of leukocytes and NK cytotoxicity.

Authors:  J Kubrycht; P Malíková; N H Huan; A Fiserová; K Bezouska; P Kruzík; K Stajner; V Moravec; M Pospísil
Journal:  Folia Microbiol (Praha)       Date:  1993       Impact factor: 2.099

7.  Channel catfish soluble FcmuR binds conserved linear epitopes present on Cmu3 and Cmu4.

Authors:  Deepak K Nayak; Aihua Tang; Melanie Wilson; Norman W Miller; Eva Bengtén
Journal:  Mol Immunol       Date:  2009-12-23       Impact factor: 4.407

8.  Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction.

Authors:  F L Ierino; M S Powell; I F McKenzie; P M Hogarth
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

9.  A transforming growth factor beta-like immunosuppressive factor in immunoglobulin G-binding factor.

Authors:  C Bouchard; A Galinha; E Tartour; W H Fridman; C Sautès
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Interleukin 13 is a B cell stimulating factor.

Authors:  T Defrance; P Carayon; G Billian; J C Guillemot; A Minty; D Caput; P Ferrara
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.